user

IS CANAGLIFLOZIN COST-EFFECTIVE COMPARED TO SITAGLIPTIN ACROSS MULTIPLE LINES OF TYPE 2 DIABETES MELLITUS (T2DM) THERAPY IN IRELAND?

被引：0
|
作者：
Bacon, T. [1 ]
Willis, M. [2 ]
Johansen, P. [2 ]
Neslusan, C. [3 ]
Nuhoho, S. [4 ]
Worbes-Cerezo, M. [5 ]
机构：
[1] Janssen Cilag Ltd, Dublin, Ireland
[2] Swedish Inst Hlth Econ, Lund, Sweden
[3] Janssen Global Serv LLC, Raritan, NJ USA
[4] Janssen Cilag AS, Birkerod, Denmark
[5] Janssen Cilag UK, High Wycombe, Bucks, England
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB76
引用
收藏
页码：A345 / A345
页数：1
相关论文
共 50 条
  • [1] SHORT-TERM ECONOMIC AND CLINICAL OUTCOMES OF CANAGLIFLOZIN COMPARED TO SITAGLIPTIN IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS (T2DM)
    Lopez, J. M.
    Martin, S.
    Ektare, V
    Patel, D.
    Rupnow, M. F.
    Botteman, M. F.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A251 - A251
  • [2] THE COST-EFFECTIVENESS OF CANAGLIFLOZIN VERSUS SITAGLIPTIN AS THIRD-LINE THERAPY IN TYPE 2 DIABETES MELLITUS (T2DM) IN A CANADIAN SETTING
    Sabapathy, S.
    Neslusan, C.
    Yoong, K.
    Teschemaker, A. R.
    Johansen, P.
    Willis, M.
    [J]. VALUE IN HEALTH, 2015, 18 (03) : A61 - A61
  • [3] COST-EFFECTIVENESS OF SAXAGLIPTIN COMPARED TO SITAGLIPTIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)
    Hutchings, A.
    Tolley, K.
    Achana, F.
    Brereton, N. J.
    Lebmeier, M.
    Mesa, O. A.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A478 - A478
  • [4] Characteristics of Patients with Type 2 Diabetes Mellitus (T2DM) Initiating Therapy with Canagliflozin
    Martin, Silas C.
    Henk, Henry J.
    Chow, Wing
    [J]. DIABETES, 2014, 63 : A307 - A307
  • [5] Canagliflozin (CANA) Compared With Sitagliptin (SITA) in Subjects With Type 2 Diabetes Mellitus (T2DM) on Metformin (MET) Over 52 Weeks
    Lavalle Gonzalez, Fernando J.
    Januszewicz, Andrzej
    Davidson, Jaime
    Qiu, Rose
    Tong, Cindy
    Meininger, Gary
    [J]. DIABETES, 2013, 62 : A61 - A61
  • [6] The cost-effectiveness of canagliflozin (CANA) versus sitagliptin (SITA) as third-line therapy in the treatment of type 2 diabetes mellitus (T2DM) in the UK
    Thompson, G.
    Schroeder, M.
    Neslusan, C.
    Willis, M.
    Johansen, P.
    Teschemaker, A.
    [J]. DIABETOLOGIA, 2014, 57 : S330 - S330
  • [7] ACHIEVEMENT OF GLYCAEMIC TARGETS WITH CANAGLIFLOZIN IN TRIPLE THERAPY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)
    Diels, J.
    Schubert, A.
    Hamilton, G.
    Canovatchel, W.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A598 - A598
  • [8] Consistent Effects of Canagliflozin (CANA) Across Racial Subgroups of Patients with Type 2 Diabetes Mellitus (T2DM)
    Gavin, James R., III
    Davies, Melanie J.
    Davies, Michael
    Vija-Purkar, Ujjwala
    Alba, Maria
    [J]. DIABETES, 2014, 63 : A285 - A285
  • [9] Cost Efficiency of Canagliflozin Versus Sitagliptin for Type 2 Diabetes Mellitus
    Ektare, Varun U.
    Lopez, Janice M. S.
    Martin, Silas C.
    Patel, Dipen A.
    Rupnow, Marcia F. T.
    Botteman, Marc F.
    [J]. AMERICAN JOURNAL OF MANAGED CARE, 2014, 20 (10): : S204 - S215
  • [10] The Cost-Effectiveness of Canagliflozin (CANA) vs. Sitagliptin as an Add-on to Metformin (MET) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the US
    Martin, Silas
    Neslusan, Cheryl
    Vo, Lien
    Teschemaker, Anna
    Johansen, Pierre
    Willis, Michael
    [J]. DIABETES, 2014, 63 : A310 - A310
12345